精優藥業(00858.HK)年度由盈轉虧1.21億港元
格隆匯6月29日丨精優藥業(00858.HK)發佈公吿,截至2021年3月31日止年度,公司收益7880萬港元,同比增長1.57%;公司擁有人應占虧損1.21億港元,上年同期溢利8328萬港元;每股虧損5.07港仙。
毛利率由55.3%輕微下降至54.0%,主要由於銷售組合變動所致。該穩定表現反映管理層在充滿挑戰及複雜的經營環境下管理集團業務付出的努力及承擔。
由盈轉虧主要歸因於與集團可換股債券投資的公平值變動虧損有關的非現金項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.